Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous and intraperitoneal paclitaxel plus oral S-1 for gastric cancer with peritoneal metastasis
ChiCTR2200056029Phase 2Completed
- Sponsor
- Ruijin Hospital
- Start
- May 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel and tegafur in gastric cancer (GC) and gastric adenocarcinoma, sponsored by Ruijin Hospital. Primary endpoint: 1-year overall survival rate. Started May 2015; status: completed.
02
Drugs
paclitaxeltegafur
03
Conditions
gastric cancer (GC)gastric adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2200056029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200056029.